February 2022

February 24, 2022

From the Co-Chairs, February 2022

Reflections on the 50th Anniversary of the National Cancer Act of 1971
February 24, 2022

Now Enrolling: EA2205 for a Rare Form of Liver Cancer

ECOG-ACRIN is leading the first randomized trial evaluating treatment strategies for patients with combined hepatocellular carcinoma-cholangiocarcinoma
February 24, 2022

Edith Mitchell Reflects on Equity Initiatives at ECOG-ACRIN

On the occasion of Black History Month, ECOG-ACRIN speaks with Edith Mitchell, MD about health equity and diversity initiatives within the Group
February 24, 2022

ECOG-ACRIN Sarcoma Working Group Builds Steam in Second Year

Kenneth Cardona, MD, FACS, of the Winship Cancer Institute at Emory University, discusses the Sarcoma Working Group’s progress to date and outlines future plans
February 24, 2022

Trial Spotlight: Nataliya Uboha on the EA2183 Trial for Esophageal and Gastric Adenocarcinoma

This randomized phase III trial explores the addition of radiotherapy to the usual treatment (chemotherapy) in patients with esophagus and stomach cancer with limited spread
February 24, 2022

Trial Results: Copanlisib in Patients with PIK3CA-Mutated Tumors

The first published results of a platform trial of PIK3CA mutations across multiple tumor types appear in the Journal of Clinical Oncology. The data are from the NCI-MATCH precision medicine trial.
February 24, 2022

News in Brief, February 2022

Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more